Literature DB >> 6773769

Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid.

F J Van Der Ouderaa, M Buytenhek, D H Nugteren, D A Van Dorp.   

Abstract

Incubation of purified prostaglandin endoperoxide synthetase from sheep vesicular glands with aspirin results in a covalent binding of the acetyl group of acetylsalicylic acid to the protein. During this acetylation, the cyclooxygenase activity is lost, but not the peroxidase activity. The reaction is completed when almost one acetyl group is bound per polypeptide chain (Mr = 68 000). After proteolysis of [3H]acetyl-protein with pronase, radioactive N-acetylserine was obtained. Originally, however, the hydroxyl group of an internal serine residue in the chain is acetylated. The formation of N-acetylserine can be explained by a rapid O leads to N acetyl shift as soon as the NH2 group of serine is liberated. A radioactive dipeptide was isolated from a thermolysin digest of the [3H]acetyl-enzyme containing phenylalanine and serine, phenylalanine being its N-terminal amino acid. Automatic Edman degradation of native and acetylated enzyme showed that only one polypeptide sequence was present: Ala-Asp-Pro-Gly-Ala-Pro-Ala-Pro-Val-Asn-Pro-X-X-Tyr-. The N-terminal sequence has an apolar character.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6773769     DOI: 10.1111/j.1432-1033.1980.tb04760.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  17 in total

1.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

Authors:  M C Walker; R G Kurumbail; J R Kiefer; K T Moreland; C M Koboldt; P C Isakson; K Seibert; J K Gierse
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

2.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

Review 3.  The eicosanoids and their biochemical mechanisms of action.

Authors:  W L Smith
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

4.  Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.

Authors:  A S Kalgutkar; B C Crews; S W Rowlinson; A B Marnett; K R Kozak; R P Remmel; L J Marnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

5.  Purification and characterization of sheep platelet cyclo-oxygenase. Acetylation by aspirin prevents haemin binding to the enzyme.

Authors:  R Boopathy; A S Balasubramanian
Journal:  Biochem J       Date:  1986-10-15       Impact factor: 3.857

Review 6.  Interactions of fatty acids, nonsteroidal anti-inflammatory drugs, and coxibs with the catalytic and allosteric subunits of cyclooxygenases-1 and -2.

Authors:  William L Smith; Michael G Malkowski
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

7.  Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation.

Authors:  R Brandt; A Dembińska-Kieć; R Korbut; R J Gryglewski; J Nowak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

8.  Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark.

Authors:  Ellen T Chang; Deirdre P Cronin-Fenton; Søren Friis; Henrik Hjalgrim; Henrik Toft Sørensen; Lars Pedersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

9.  Benzimidazole covalent probes and the gastric H(+)/K(+)-ATPase as a model system for protein labeling in a copper-free setting.

Authors:  Chelsea J Paresi; Qi Liu; Yue-Ming Li
Journal:  Mol Biosyst       Date:  2016-05

10.  Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins.

Authors:  Adam J T Smith; Xiyun Zhang; Andrew G Leach; K N Houk
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.